Presentation on theme: "EBM Journal Club Sarah Jean Strube, D. O. Resident Physician St"— Presentation transcript:
1EBM Journal Club Sarah Jean Strube, D. O. Resident Physician St EBM Journal Club Sarah Jean Strube, D.O. Resident Physician St. Mary Medical Center October 17, 2008
2Overview Topic Background Defining the patient Article MethodsResultsStatisticsAuthor’s conclusionStatistics discussion
3TopicReperfusion injury status post PCI in acute myocardial infarction with and without cyclosporine injection on area of infarction.
4BackgroundMyocardial infarction is a disabling disease and infarct size is considered a major determining factor for mortality. Limiting the size of an infarct through reperfusion therapy is an important strategy in decreasing morbidity whether through thrombolysis or PCI. However, reperfusion has its own detrimental effects through several mechanisms. One of which is via mitochondrial dysfunction.
5BackgroundMitochondrial dysfunction has been termed “permeability transition.” It is the opening of a nonspecific channel in the inner membrane of the mitochondria. This transition results in uncoupling of the respiratory chain and collapse of the inner mitochondrial membrane potential with subsequent efflux of proapoptotic factors causing myocardiocyte death.
6BACKGROUNDCyclosporine is mostly known for its immunosuppressive effects.However, it has been found by several researchers in experimental models to have potent inhibiting effects on mitochondrial permeability transition and may prevent ischemia/reperfusion injury.
8PICO questionPatient: A 65 YO male with a Hx of HTN, dyslipidemia and prior tobacco use presented to the Emergency Department with prolonged angina pectoris. Onset of his CP was six hours prior to admission and he was found to have an acute ST-segment elevation in two contiguous precordial leads along with elevation of CK and troponin I. An acute myocardial infarction was Dx and he was considered a candidate for urgent PCI.
9PICO QUESTIONIntervention: Administration of cyclosporine via IV bolus at time of urgent PCI but prior to stenting of an occluded artery (TIMI flow 0) in an acute ongoing myocardial infarction
10PICO QuestionControl: NS bolus during PCI with stenting alone prior to the procedure in an occluded artery (TIMI flow 0).
11PICO questionOutcome: did the intervention with pretreatment with cyclosporine vs normal saline decrease the area of myocardial infarction SP PCI?
12To evaluate the efficacy of a therapy Article selected Effect of cyclosporine on reperfusion injury in acute myocardial infarction. New England Journal of Medicine 2008; 359:Research objective:To evaluate the efficacy of a therapy
13The article Original research, pilot study Prospective, multicenter, randomized, single blind, controlled trialJournal - peer reviewed, general Internal Medicine, highly respectedSites – multicenterPatients – 58 randomly assigned, 30 CS 28 control
14Patient Criteria EXCLUSION INCLUSION Cardiac arrest Cardiogenic shock Vent fibrillationStent thrombosisPrevious MIAngina wi 48hOccl LM/Circ or collateralsHypersensitivity to cyclosporineINCLUSIONMale/female 18y or older present wi 12h of CPSTEMI 0.1 mV 2 cont leadsPCI eligibleTIMI flow grade 0 at time of admission
15Other exclusions: Renal or liver failure Uncontrolled hypertension PregnancyWomen of childbearing age not on contraceptionAny Ds of immunologic dysfunction; CA, HIV, hepatitis
17Study PopulationJuly 2005 to October patients at three centers were hospitalized for management of acute MIApproximately 80% men, mean age 58y230 underwent PCI, 24 not enrolled - inadequate manpower; 148 excluded, see belowBaseline characteristics of subjects were similar
18Study PopulationSimilar in ischemia time, myocardium at risk and EF prior to PCI - MRIThombolytic therapy failed in 13 patients prior to PCI, 8 in control, 5 in CSCulprit lesion stented in all patients and only infarct related lesions treatedFour patients, TIMI 2 flow was not achieved SP PCI
19Study Population Baseline Characteristics Men/women - 25/5 mean age 58 +/- 2yBMI mean 26 +/- 1, dyslipidemia 14, HTN 15, DM 4HX CAD 4Tobacco 17ControlMen/women – 21/7 mean age 57 +/- 2yBMI mean 27 +/- 1, dyslipidemia 12, HTN 13 , DM 4HX CAD 4Tobacco 16
21MethodsRandomization: after coronary angio, before stent, a computer generated sequence assigned patients to receive placebo vs cyclosporineIntervention:IV bolus of cyclosporine 2.5mg/kg of BW, control given equivalent volume in NS
22Blood Concentration of Cyclosporine during Reperfusion Figure 4. Blood Concentration of Cyclosporine during Reperfusion. The whole-blood concentration of cyclosporine is shown at various times during early reperfusion. T bars denote standard errors.Piot C et al. N Engl J Med 2008;359:
23Statistical AnalysisCalculated target sample size of 62 pts based on prior trial, 31 per groupHypothesized that CS would reduce the AUC for CK release by 30% for a power of 80%Probability of a type I error of 0.05 using a two sided testBetween group comparisons for AUC for trop, CK, area at risk, and infarct size by MRI evaluated with Wilcoxon rank-sum
24Statistical AnalysisAnalysis of covariance performed on the equality of slopes on the regression of infarct size on the area at risk in CS and controlComparison of incidence of cumulative adverse events between groups using Fisher exact test
25END POINTSPrimary : size of the infarct assessed by measurements of cardiac biomarkersSecondary : size of infarct measured by area of hyper-enhancement seen on cardiac MRI, assessed day 5
26END POINTSOther: major adverse events first 48h including death, MI, heart failure, stroke, recurrent ischemia, renal/liver insufficiency, vascular complications, and bleeding
27RESULTSThe cyclosporine and the control group were similar in ischemia time, area of myocardium at risk and EF prior to PCI
28RESULTS Assessment of infarct size by biomarkers: CK release sig decreased in CS group vs control group over time (P=0.04)Trop I not sig decreased in CS group vs control group over time (P=0.15)
29RESULTS Infarct size as a function of area at risk For any given area at risk CS administration was associated with a reduction infarct size as measured by CK/trop I release (P=0.006) / (P=0.002)
30Assessment of Infarct Size by Biomarker Measurement Figure 1. Assessment of Infarct Size by Biomarker Measurement. Serum creatine kinase was measured every 4 hours on day 1 and every 6 hours on days 2 and 3 after coronary reperfusion. Curves for the control and cyclosporine groups are shown in Panel A. Cyclosporine administration (Adm.) resulted in a significant reduction in infarct size of approximately 40% as measured by creatine kinase release. Serum troponin I was measured every 4 hours on day 1 and every 6 hours on days 2 and 3 after coronary reperfusion. Curves for the control and cyclosporine groups are shown in Panel B. Cyclosporine administration did not result in a significant reduction in infarct size as measured by troponin I release. T bars denote standard errors.Piot C et al. N Engl J Med 2008;359:
31Infarct Size as a Function of the Area at Risk Figure 2. Infarct Size as a Function of the Area at Risk. The area under the curve (AUC) for serum creatine kinase release was expressed as a function of the circumferential extent of abnormally contracting segments (ACS), an estimate of the area at risk, as shown in Panel A. There was a significant correlation between the two variables in the control group (r2=0.60). Data points for the cyclosporine group (r2=0.34) lie below the regression line for the control group. These data indicate that, for any given area at risk, cyclosporine administration was associated with a reduction in the resulting infarct size as measured by creatine kinase release. This difference was significant by analysis of covariance (P=0.006). There was also a significant correlation between the AUC for troponin I release and the area at risk in the control group (r2=0.54), as shown in Panel B. Data points for the cyclosporine group (r2=0.26) lie below the regression line for the control group. These data indicate that, for any given area at risk, cyclosporine administration was associated with a reduction in the resulting infarct size as measured by troponin I release. This difference was confirmed to be significant by analysis of covariance (P=0.002).Piot C et al. N Engl J Med 2008;359:
32MRI or CMRMRI has been used since 1984 on imaging of the heart and recently improved technology with contrast enhancement improves delineation of hyper-enhanced regions (acute MI)
34RESULTS Subgroup analysis 27 patients: Infarct size (absolute mass) decreased on MRI day 5 in CS group 37 g vs 46 g control group (P=0.04)Area of infarction:E A X slice thick X M sd
35Typical Cine Image and Contrast-Enhanced Image Obtained by MRI before Revascularization Figure 1. Typical Cine Image and Contrast-Enhanced Image Obtained by MRI before Revascularization. Registration of the images was not required, because both types were acquired during the same MRI session. Twelve equal circumferential segments were analyzed in each short-axis view. For contrast-enhanced images, the transmural extent of hyperenhancement was determined for each segment with use of the following equation: percentage of area that was hyperenhanced = 100 x area A / (area A + area B).Kim R et al. N Engl J Med 2000;343:
36Typical Contrast-Enhanced Images Obtained by MRI in a Short-Axis View (Upper Panels) and a Long-Axis View (Lower Panels) in Three PatientsFigure 2. Typical Contrast-Enhanced Images Obtained by MRI in a Short-Axis View (Upper Panels) and a Long-Axis View (Lower Panels) in Three Patients. Hyperenhancement is present (arrows) in various coronary-perfusion territories -- the left anterior descending coronary artery, the left circumflex artery, and the right coronary artery -- with a range of transmural involvement.Kim R et al. N Engl J Med 2000;343:
37Assessment of Infarct Size by Magnetic Resonance Imaging (MRI) Figure 3. Assessment of Infarct Size by Magnetic Resonance Imaging (MRI). The size of the area of late hyperenhancement on MRI is presented for 11 patients in the control group (black circles) and 16 patients in the cyclosporine group (white circles). The mean infarct size as assessed by MRI was significantly greater in the control group (black square) than in the cyclosporine group (white square). The size of the area of late hyperenhancement was calculated with the use of the following formula: infarct mass (in grams of tissue)=S (hyperenhanced area [in square centimeters])×slice thickness (in centimeters)×myocardial specific density (1.05 g per cubic centimeter). P=0.04 for the comparison with the control group.Piot C et al. N Engl J Med 2008;359:
38Author’s ConclusionThe effect of CS in this small pilot study of patients having an acute myocardial infarction undergoing PCI, showed a decrease in infarct size as measured by release of CK and delayed hyper-enhancement on MRI.Trop I was not significantly reduced by CS
39EvaluationMethods:randomized, but unclear if truly similar in ischemia timeBlinded to full extent allowableAll patients accounted forSubgroup was noted beforehand (MRI) and not added later because of Tx effectsSmall population but was a pilot study
40Evaluation Outcomes Results definitely applied to my patient Results are meaningful, however difficult to know if truly affected mortalityCS did show Tx effect especially in MRI group with proven validity of acute MI hyper-enhancement
41Statistics Discussion To reviewBetween group comparisons for AUC for trop, CK, area at risk, and infarct size by MRI evaluated with Wilcoxon rank-sumAUC for normal data is a Gaussian distribution and the usual parametric stats can be usedWith non normal data (continuous or ordinal data) nonparametric stats like Wilcoxin rank sum can be used
44Wilcoxin Rank SumA descriptive nonparametric statistic using non normal data. Similar to performing a two sample t testWhy use Wilcoxin?Appropriate for small populationEasier to interpret ordinal or continuous dataNo assumption of population distributionMore robust
45Wilcoxin Rank Sum Disadvantages Less sensitive Less power Not appropriate for large N
46Wicoxin Rank Sum The procedure: Arrange observations for both groups into a single rank seriesAdd up the ranks for both seriesThe rank sum is then divided by the number of observationsObserve the rank sum difference, as the magnitude tells you how close the groups are
47Wicoxin Rank Sum Example CA NV 4 2 5 3 6 7 8 9 10 11 Imagine choosing an Olympic Team of Karate experts from two states, CA and NV. Your decision is based on how many boards each athlete can break in 5 minutesStatistics in a NutshellCANV425367891011